SGLT2 Inhibition in Heart Failure: New Updates

Published: 08 February 2023

  • Views:

    Views Icon 10512
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 5
    Panel Discussion
    Harriette Van Spall, Nandini Gupta, Subodh Verma, John JV McMurray, Xiaowen “Wendy” Wang, Pardeep Jhund
    Up Next
  • episode_image
    12m 35s
    Part 10 Panel Discussion
    Harriette Van Spall, Nandini Gupta, Scott Solomon, Muthiah Vaduganathan, Orly Vardeny, Eileen O’Meara
Average (ratings)
No ratings
Your rating

Overview

This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.

 

Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.

 

Note, the live version of this session was CME accredited; this on-demand version is not.

This programme is supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
  • To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
  • To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
  • To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
  • To assess the merit of ejection fraction in heart failure care

Target Audience

  • Primary Care Physicians
  • Endocrinologists
  • Nephrologists
  • Cardiologists
  • Nurses
  • Pharmacists
  • Dietitians
  • Diabetes Educators

More from this programme

Part 1

Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?

Part 2

SGLT2 Inhibition in the Elderly and Frail Patients

Part 3

Gender Differences in Outcomes With SGLT2 Inhibitors

Part 4

Efficacy and Safety of SGLT2 Inhibitors in Black Patients

Part 5

Panel Discussion

Part 6

SGLT2 Inhibition in Patients With Improved EF

Part 7

SGLT2 Inhibition With MRAs and ARNis

Part 8

Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?

Part 9

Does EF Still Matter in HF Management?

Part 10

Panel Discussion

Faculty Biographies

Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.

She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.

Dr Van Spall is an Editorial Board…

View full profile
Nandini Gupta

Nandini Gupta

Cardiologist

View full profile
Subodh Verma

Subodh Verma

Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.

Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.

View full profile
John JV McMurray

John JV McMurray

Professor of Cardiology

Prof John McMurray is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. A graduate of Manchester University, Prof McMurray completed postgraduate research at the University of Dundee.

Prof McMurray is a Fellow of the European Society of Cardiology (ESC), American College of Cardiology and American Heart Association as well as the medical Royal Colleges in Edinburgh and Glasgow and the Royal Society of Edinburgh and UK Academy of Medical Sciences.

View full profile

Xiaowen Wang

Cardiovascular Medicine Fellow

View full profile
Pardeep Jhund

Pardeep Jhund

Professor in Cardiology, University of Glasgow

Prof Pardeep Jhund is a Professor in Cardiology at the University of Glasgow, UK.

He trained in medicine at the University of Glasgow, and completed his general medical training in Edinburgh. During this time he also graduated with a MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, London, UK.

Prior to this, he graduated from the University of Glasgow with a PhD in cardiovascular epidemiology, under the tutelage of Prof John McMurray, and completed his fellowship at The Brigham and Women’s Hospital, Boston, US.

Prof Jhund has a special interest in heart failure, around which he has published widely in leading international journals.

View full profile